Marginal Zone Lymphoma: 2026 Update on Diagnosis and Management - PubMed
5 hours ago
- #Marginal Zone Lymphoma
- #MZL Treatment
- #MZL Diagnosis
- Marginal Zone Lymphoma (MZL) is a heterogeneous group of indolent mature B-cell neoplasms with three major subtypes: nodal, splenic, and extranodal MALT.
- Diagnosis is advanced by genomic testing, PET/CT, and emerging use of circulating tumor DNA. RECLASS classification and FIL-NF10 introduced a fourth subtype, disseminated MZL.
- Prognosis varies by subtype and stage, with MZL IPI and FLIPI24 indices used for prognostication.
- Frontline treatment differs for localized (radiotherapy, anti-microbial, rituximab) vs. advanced-stage (systemic immunotherapy ± chemotherapy, cBTKi-based regimens).
- Relapsed/refractory MZL treatments include cBTKi, immunomodulators, with emerging data for antibody-drug conjugates, T-cell engagers, and CAR T-cell therapies.